img

Global Pancreatic Endocrine Tumor Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pancreatic Endocrine Tumor Drug Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Pancreatic Endocrine Tumor Drug report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pancreatic Endocrine Tumor Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Clinic and Research Center are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pancreatic Endocrine Tumor Drug industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pancreatic Endocrine Tumor Drug key manufacturers include Ipsen S.A., Jiangsu Hengrui Medicine Co., Ltd., MediaPharma s.r.l., Novartis AG and OXiGENE, Inc., etc. Ipsen S.A., Jiangsu Hengrui Medicine Co., Ltd., MediaPharma s.r.l. are top 3 players and held % sales share in total in 2022.
Pancreatic Endocrine Tumor Drug can be divided into Buparlisib Hydrochloride, Dovitinib Lactate, Fosbretabulin Tromethamine and Lanreotide Acetate, etc. Buparlisib Hydrochloride is the mainstream product in the market, accounting for % sales share globally in 2022.
Pancreatic Endocrine Tumor Drug is widely used in various fields, such as Clinic, Research Center and Hospital,, etc. Clinic provides greatest supports to the Pancreatic Endocrine Tumor Drug industry development. In 2022, global % sales of Pancreatic Endocrine Tumor Drug went into Clinic filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pancreatic Endocrine Tumor Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Ipsen S.A.
Jiangsu Hengrui Medicine Co., Ltd.
MediaPharma s.r.l.
Novartis AG
OXiGENE, Inc.
Segment by Type
Buparlisib Hydrochloride
Dovitinib Lactate
Fosbretabulin Tromethamine
Lanreotide Acetate
MPHE-001B
Others

Segment by Application


Clinic
Research Center
Hospital

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pancreatic Endocrine Tumor Drug market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pancreatic Endocrine Tumor Drug, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pancreatic Endocrine Tumor Drug industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Pancreatic Endocrine Tumor Drug in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pancreatic Endocrine Tumor Drug introduction, etc. Pancreatic Endocrine Tumor Drug Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Pancreatic Endocrine Tumor Drug market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Pancreatic Endocrine Tumor Drug Market Overview
1.1 Pancreatic Endocrine Tumor Drug Product Overview
1.2 Pancreatic Endocrine Tumor Drug Market Segment by Type
1.2.1 Buparlisib Hydrochloride
1.2.2 Dovitinib Lactate
1.2.3 Fosbretabulin Tromethamine
1.2.4 Lanreotide Acetate
1.2.5 MPHE-001B
1.2.6 Others
1.3 Global Pancreatic Endocrine Tumor Drug Market Size by Type
1.3.1 Global Pancreatic Endocrine Tumor Drug Market Size Overview by Type (2018-2034)
1.3.2 Global Pancreatic Endocrine Tumor Drug Historic Market Size Review by Type (2018-2024)
1.3.3 Global Pancreatic Endocrine Tumor Drug Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2018-2024)
1.4.2 Europe Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Breakdown by Type (2018-2024)
2 Global Pancreatic Endocrine Tumor Drug Market Competition by Company
2.1 Global Top Players by Pancreatic Endocrine Tumor Drug Sales (2018-2024)
2.2 Global Top Players by Pancreatic Endocrine Tumor Drug Revenue (2018-2024)
2.3 Global Top Players by Pancreatic Endocrine Tumor Drug Price (2018-2024)
2.4 Global Top Manufacturers Pancreatic Endocrine Tumor Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Pancreatic Endocrine Tumor Drug Market Competitive Situation and Trends
2.5.1 Pancreatic Endocrine Tumor Drug Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Pancreatic Endocrine Tumor Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pancreatic Endocrine Tumor Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Pancreatic Endocrine Tumor Drug Market
2.8 Key Manufacturers Pancreatic Endocrine Tumor Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Pancreatic Endocrine Tumor Drug Status and Outlook by Region
3.1 Global Pancreatic Endocrine Tumor Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Pancreatic Endocrine Tumor Drug Historic Market Size by Region
3.2.1 Global Pancreatic Endocrine Tumor Drug Sales in Volume by Region (2018-2024)
3.2.2 Global Pancreatic Endocrine Tumor Drug Sales in Value by Region (2018-2024)
3.2.3 Global Pancreatic Endocrine Tumor Drug Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Pancreatic Endocrine Tumor Drug Forecasted Market Size by Region
3.3.1 Global Pancreatic Endocrine Tumor Drug Sales in Volume by Region (2024-2034)
3.3.2 Global Pancreatic Endocrine Tumor Drug Sales in Value by Region (2024-2034)
3.3.3 Global Pancreatic Endocrine Tumor Drug Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Pancreatic Endocrine Tumor Drug by Application
4.1 Pancreatic Endocrine Tumor Drug Market Segment by Application
4.1.1 Clinic
4.1.2 Research Center
4.1.3 Hospital
4.2 Global Pancreatic Endocrine Tumor Drug Market Size by Application
4.2.1 Global Pancreatic Endocrine Tumor Drug Market Size Overview by Application (2018-2034)
4.2.2 Global Pancreatic Endocrine Tumor Drug Historic Market Size Review by Application (2018-2024)
4.2.3 Global Pancreatic Endocrine Tumor Drug Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2018-2024)
4.3.2 Europe Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Breakdown by Application (2018-2024)
5 North America Pancreatic Endocrine Tumor Drug by Country
5.1 North America Pancreatic Endocrine Tumor Drug Historic Market Size by Country
5.1.1 North America Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2018-2024)
5.1.3 North America Pancreatic Endocrine Tumor Drug Sales in Value by Country (2018-2024)
5.2 North America Pancreatic Endocrine Tumor Drug Forecasted Market Size by Country
5.2.1 North America Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2024-2034)
5.2.2 North America Pancreatic Endocrine Tumor Drug Sales in Value by Country (2024-2034)
6 Europe Pancreatic Endocrine Tumor Drug by Country
6.1 Europe Pancreatic Endocrine Tumor Drug Historic Market Size by Country
6.1.1 Europe Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2018-2024)
6.1.3 Europe Pancreatic Endocrine Tumor Drug Sales in Value by Country (2018-2024)
6.2 Europe Pancreatic Endocrine Tumor Drug Forecasted Market Size by Country
6.2.1 Europe Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2024-2034)
6.2.2 Europe Pancreatic Endocrine Tumor Drug Sales in Value by Country (2024-2034)
7 Asia-Pacific Pancreatic Endocrine Tumor Drug by Region
7.1 Asia-Pacific Pancreatic Endocrine Tumor Drug Historic Market Size by Region
7.1.1 Asia-Pacific Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Pancreatic Endocrine Tumor Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Pancreatic Endocrine Tumor Drug Sales in Value by Region (2024-2034)
8 Latin America Pancreatic Endocrine Tumor Drug by Country
8.1 Latin America Pancreatic Endocrine Tumor Drug Historic Market Size by Country
8.1.1 Latin America Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2018-2024)
8.1.3 Latin America Pancreatic Endocrine Tumor Drug Sales in Value by Country (2018-2024)
8.2 Latin America Pancreatic Endocrine Tumor Drug Forecasted Market Size by Country
8.2.1 Latin America Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2024-2034)
8.2.2 Latin America Pancreatic Endocrine Tumor Drug Sales in Value by Country (2024-2034)
9 Middle East and Africa Pancreatic Endocrine Tumor Drug by Country
9.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Historic Market Size by Country
9.1.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Pancreatic Endocrine Tumor Drug Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Ipsen S.A.
10.1.1 Ipsen S.A. Company Information
10.1.2 Ipsen S.A. Introduction and Business Overview
10.1.3 Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Ipsen S.A. Pancreatic Endocrine Tumor Drug Products Offered
10.1.5 Ipsen S.A. Recent Development
10.2 Jiangsu Hengrui Medicine Co., Ltd.
10.2.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
10.2.2 Jiangsu Hengrui Medicine Co., Ltd. Introduction and Business Overview
10.2.3 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Products Offered
10.2.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Development
10.3 MediaPharma s.r.l.
10.3.1 MediaPharma s.r.l. Company Information
10.3.2 MediaPharma s.r.l. Introduction and Business Overview
10.3.3 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2024)
10.3.4 MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Products Offered
10.3.5 MediaPharma s.r.l. Recent Development
10.4 Novartis AG
10.4.1 Novartis AG Company Information
10.4.2 Novartis AG Introduction and Business Overview
10.4.3 Novartis AG Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Novartis AG Pancreatic Endocrine Tumor Drug Products Offered
10.4.5 Novartis AG Recent Development
10.5 OXiGENE, Inc.
10.5.1 OXiGENE, Inc. Company Information
10.5.2 OXiGENE, Inc. Introduction and Business Overview
10.5.3 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales, Revenue and Gross Margin (2018-2024)
10.5.4 OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Products Offered
10.5.5 OXiGENE, Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Pancreatic Endocrine Tumor Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Pancreatic Endocrine Tumor Drug Industrial Chain Analysis
11.4 Pancreatic Endocrine Tumor Drug Market Dynamics
11.4.1 Pancreatic Endocrine Tumor Drug Industry Trends
11.4.2 Pancreatic Endocrine Tumor Drug Market Drivers
11.4.3 Pancreatic Endocrine Tumor Drug Market Challenges
11.4.4 Pancreatic Endocrine Tumor Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Pancreatic Endocrine Tumor Drug Distributors
12.3 Pancreatic Endocrine Tumor Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Buparlisib Hydrochloride
Table 2. Major Company of Dovitinib Lactate
Table 3. Major Company of Fosbretabulin Tromethamine
Table 4. Major Company of Lanreotide Acetate
Table 5. Major Company of MPHE-001B
Table 6. Major Company of Others
Table 7. Global Pancreatic Endocrine Tumor Drug Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Pancreatic Endocrine Tumor Drug Sales by Type (2018-2024) & (K Pcs)
Table 9. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type (2018-2024)
Table 10. Global Pancreatic Endocrine Tumor Drug Sales by Type (2018-2024) & (US& Million)
Table 11. Global Pancreatic Endocrine Tumor Drug Market Share in Value by Type (2018-2024)
Table 12. Global Pancreatic Endocrine Tumor Drug Price by Type (2018-2024) & (USD/Pcs)
Table 13. Global Pancreatic Endocrine Tumor Drug Sales by Type (2024-2034) & (K Pcs)
Table 14. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type (2024-2034)
Table 15. Global Pancreatic Endocrine Tumor Drug Sales by Type (2024-2034) & (US$ Million)
Table 16. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type (2024-2034)
Table 17. Global Pancreatic Endocrine Tumor Drug Price by Type (2024-2034) & (USD/Pcs)
Table 18. North America Pancreatic Endocrine Tumor Drug Sales by Type (2018-2024) & (K Pcs)
Table 19. North America Pancreatic Endocrine Tumor Drug Sales by Type (2018-2024) & (US$ Million)
Table 20. Europe Pancreatic Endocrine Tumor Drug Sales (K Pcs) by Type (2018-2024)
Table 21. Europe Pancreatic Endocrine Tumor Drug Sales by Type (2018-2024) & (US$ Million)
Table 22. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales (K Pcs) by Type (2018-2024)
Table 23. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Type (2018-2024) & (US$ Million)
Table 24. Latin America Pancreatic Endocrine Tumor Drug Sales (K Pcs) by Type (2018-2024)
Table 25. Latin America Pancreatic Endocrine Tumor Drug Sales by Type (2018-2024) & (US$ Million)
Table 26. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales (K Pcs) by Type (2018-2024)
Table 27. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Type (2018-2024) & (US$ Million)
Table 28. Global Pancreatic Endocrine Tumor Drug Sales by Company (2018-2024) & (K Pcs)
Table 29. Global Pancreatic Endocrine Tumor Drug Sales Share by Company (2018-2024)
Table 30. Global Pancreatic Endocrine Tumor Drug Revenue by Company (2018-2024) & (US$ Million)
Table 31. Global Pancreatic Endocrine Tumor Drug Revenue Share by Company (2018-2024)
Table 32. Global Market Pancreatic Endocrine Tumor Drug Price by Company (2018-2024) & (USD/Pcs)
Table 33. Global Pancreatic Endocrine Tumor Drug Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 34. Global Pancreatic Endocrine Tumor Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 35. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pancreatic Endocrine Tumor Drug as of 2022)
Table 36. Date of Key Manufacturers Enter into Pancreatic Endocrine Tumor Drug Market
Table 37. Key Manufacturers Pancreatic Endocrine Tumor Drug Product Type
Table 38. Mergers & Acquisitions, Expansion Plans
Table 39. Global Pancreatic Endocrine Tumor Drug Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 40. Global Pancreatic Endocrine Tumor Drug Sales by Region (2018-2024) & (K Pcs)
Table 41. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Region (2018-2024)
Table 42. Global Pancreatic Endocrine Tumor Drug Sales by Region (2018-2024) & (US$ Million)
Table 43. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Region (2018-2024)
Table 44. Global Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 45. Global Pancreatic Endocrine Tumor Drug Sales by Region (2024-2034) & (K Pcs)
Table 46. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Region (2024-2034)
Table 47. Global Pancreatic Endocrine Tumor Drug Sales by Region (2024-2034) & (US$ Million)
Table 48. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Region (2024-2034)
Table 49. Global Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 50. Global Pancreatic Endocrine Tumor Drug Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 51. Global Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) & (K Pcs)
Table 52. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application (2018-2024)
Table 53. Global Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) & (US$ Million)
Table 54. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application (2018-2024)
Table 55. Global Pancreatic Endocrine Tumor Drug Price by Application (2018-2024) & (USD/Pcs)
Table 56. Global Pancreatic Endocrine Tumor Drug Sales by Application (2024-2034) & (K Pcs)
Table 57. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application (2024-2034)
Table 58. Global Pancreatic Endocrine Tumor Drug Sales by Application (2024-2034) & (US$ Million)
Table 59. Global Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application (2024-2034)
Table 60. Global Pancreatic Endocrine Tumor Drug Price by Application (2024-2034) & (USD/Pcs)
Table 61. North America Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) (K Pcs)
Table 62. North America Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) & (US$ Million)
Table 63. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) (K Pcs)
Table 64. Europe Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) & (US$ Million)
Table 65. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) (K Pcs)
Table 66. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) & (US$ Million)
Table 67. Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) (K Pcs)
Table 68. Latin America Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) & (US$ Million)
Table 69. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) (K Pcs)
Table 70. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Application (2018-2024) & (US$ Million)
Table 71. North America Pancreatic Endocrine Tumor Drug Sales by Country (2018-2024) & (K Pcs)
Table 72. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Country (2018-2024)
Table 73. North America Pancreatic Endocrine Tumor Drug Sales by Country (2018-2024) & (US$ Million)
Table 74. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Country (2018-2024)
Table 75. North America Pancreatic Endocrine Tumor Drug Sales by Country (2024-2034) & (K Pcs)
Table 76. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Country (2024-2034)
Table 77. North America Pancreatic Endocrine Tumor Drug Sales by Country (2024-2034) & (US$ Million)
Table 78. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Country (2024-2034)
Table 79. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2018-2024) & (K Pcs)
Table 80. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Country (2018-2024)
Table 81. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2018-2024) & (US$ Million)
Table 82. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Country (2018-2024)
Table 83. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2024-2034) & (K Pcs)
Table 84. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Country (2024-2034)
Table 85. Europe Pancreatic Endocrine Tumor Drug Sales by Country (2024-2034) & (US$ Million)
Table 86. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Country (2024-2034)
Table 87. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2018-2024) & (K Pcs)
Table 88. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Region (2018-2024)
Table 89. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2018-2024) & (US$ Million)
Table 90. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Region (2018-2024)
Table 91. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2024-2034) & (K Pcs)
Table 92. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Region (2024-2034)
Table 93. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales by Region (2024-2034) & (US$ Million)
Table 94. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Region (2024-2034)
Table 95. Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2018-2024) & (K Pcs)
Table 96. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Country (2018-2024)
Table 97. Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2018-2024) & (US$ Million)
Table 98. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Country (2018-2024)
Table 99. Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2024-2034) & (K Pcs)
Table 100. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Country (2024-2034)
Table 101. Latin America Pancreatic Endocrine Tumor Drug Sales by Country (2024-2034) & (US$ Million)
Table 102. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Country (2024-2034)
Table 103. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2018-2024) & (K Pcs)
Table 104. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Country (2018-2024)
Table 105. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2018-2024) & (US$ Million)
Table 106. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Country (2018-2024)
Table 107. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2024-2034) & (K Pcs)
Table 108. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Country (2024-2034)
Table 109. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales by Country (2024-2034) & (US$ Million)
Table 110. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Country (2024-2034)
Table 111. Ipsen S.A. Company Information
Table 112. Ipsen S.A. Introduction and Business Overview
Table 113. Ipsen S.A. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 114. Ipsen S.A. Pancreatic Endocrine Tumor Drug Product
Table 115. Ipsen S.A. Recent Development
Table 116. Jiangsu Hengrui Medicine Co., Ltd. Company Information
Table 117. Jiangsu Hengrui Medicine Co., Ltd. Introduction and Business Overview
Table 118. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 119. Jiangsu Hengrui Medicine Co., Ltd. Pancreatic Endocrine Tumor Drug Product
Table 120. Jiangsu Hengrui Medicine Co., Ltd. Recent Development
Table 121. MediaPharma s.r.l. Company Information
Table 122. MediaPharma s.r.l. Introduction and Business Overview
Table 123. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 124. MediaPharma s.r.l. Pancreatic Endocrine Tumor Drug Product
Table 125. MediaPharma s.r.l. Recent Development
Table 126. Novartis AG Company Information
Table 127. Novartis AG Introduction and Business Overview
Table 128. Novartis AG Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 129. Novartis AG Pancreatic Endocrine Tumor Drug Product
Table 130. Novartis AG Recent Development
Table 131. OXiGENE, Inc. Company Information
Table 132. OXiGENE, Inc. Introduction and Business Overview
Table 133. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 134. OXiGENE, Inc. Pancreatic Endocrine Tumor Drug Product
Table 135. OXiGENE, Inc. Recent Development
Table 136. Key Raw Materials Lists
Table 137. Raw Materials Key Suppliers Lists
Table 138. Pancreatic Endocrine Tumor Drug Market Trends
Table 139. Pancreatic Endocrine Tumor Drug Market Drivers
Table 140. Pancreatic Endocrine Tumor Drug Market Challenges
Table 141. Pancreatic Endocrine Tumor Drug Market Restraints
Table 142. Pancreatic Endocrine Tumor Drug Distributors List
Table 143. Pancreatic Endocrine Tumor Drug Downstream Customers
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Pancreatic Endocrine Tumor Drug Product Picture
Figure 2. Global Pancreatic Endocrine Tumor Drug Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pancreatic Endocrine Tumor Drug Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Pancreatic Endocrine Tumor Drug Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of Buparlisib Hydrochloride
Figure 6. Global Buparlisib Hydrochloride Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Dovitinib Lactate
Figure 8. Global Dovitinib Lactate Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of Fosbretabulin Tromethamine
Figure 10. Global Fosbretabulin Tromethamine Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Lanreotide Acetate
Figure 12. Global Lanreotide Acetate Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of MPHE-001B
Figure 14. Global MPHE-001B Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of Others
Figure 16. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Global Pancreatic Endocrine Tumor Drug Sales by Type (2018-2034) & (US$ Million)
Figure 18. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Type in 2022 & 2034
Figure 19. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2022
Figure 20. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2022
Figure 21. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2022
Figure 22. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2022
Figure 23. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2022
Figure 24. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2022
Figure 25. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2022
Figure 26. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2022
Figure 27. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Type in 2022
Figure 28. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Type in 2022
Figure 29. The 5 and 10 Largest Manufacturers in the World: Market Share by Pancreatic Endocrine Tumor Drug Sales in 2022
Figure 30. The 5 and 10 Largest Manufacturers in the World: Market Share by Pancreatic Endocrine Tumor Drug Revenue in 2022
Figure 31. Pancreatic Endocrine Tumor Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Product Picture of Clinic
Figure 33. Global Clinic Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Product Picture of Research Center
Figure 35. Global Research Center Sales YoY Growth (2018-2034) & (K Pcs)
Figure 36. Product Picture of Hospital
Figure 37. Global Hospital Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Global Pancreatic Endocrine Tumor Drug Sales by Application (2018-2034) & (US$ Million)
Figure 39. Global Pancreatic Endocrine Tumor Drug Sales Market Share by Application in 2022 & 2034
Figure 40. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application in 2022
Figure 41. North America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2022
Figure 42. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application in 2022
Figure 43. Europe Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2022
Figure 44. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application in 2022
Figure 45. Asia-Pacific Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2022
Figure 46. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Volume by Application in 2022
Figure 47. Latin America Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2022
Figure 48. Middle East and Africa Pancreatic Endocrine Tumor Drug Sales Market Share in Value by Application in 2022
Figure 49. Key Raw Materials Price
Figure 50. Pancreatic Endocrine Tumor Drug Manufacturing Cost Structure
Figure 51. Pancreatic Endocrine Tumor Drug Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries